Method for eliminating potentially toxic and/or harmful substances

• US 20040115278A1
• Filed: 09/29/2003
• Published: 06/17/2004
• Est. Priority Date: 04/05/2001
• Status: Abandoned Application

• Current Assignee: Heinrich Wieland
• Original Assignee: Gerhard Putz, Jurgen Eckes
• Inventors: Eckes, Jurgen, Putz, Gerhard
• Application Number:
  US10/473,610
• Publication Number:
  US 20040115278A1
• Time in Patent Office: Days
• US Class Current: 424/489
• CPC Class Codes: A61K 9/127 Liposomes
• CPC Class Codes: A61M 1/3482 by filtrating the filtrate using another cross-flow filter, e.g. a membrane filter
• CPC Class Codes: A61M 1/3486 Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
• CPC Class Codes: A61M 1/362 changing physical properties of target cells by binding them to added particles to facilitate their subsequent separation from other cells, e.g. immunoaffinity
• CPC Class Codes: A61M 1/3679 by absorption A61M1/3675 takes precedence

Abstract

The invention describes a method for eliminating potentially toxic and/or harmful substances, whereing particles which are capable of binding, taking up and/or carrying the toxic and/or harmful substances, are removed from a body fluid in an extracorporeal step or in an extrinsic or exogeneous device.

Claims

1. Method for eliminating potentially toxic and/or harmful substances, characterized in that particles, which are capable of binding, taking up and/or carrying the toxic and/or harmful substances, are removed from a body fluid in an extracorporeal step or in an extrinsic or exogeneous device.

2. Method according to claim 1, wherein the particles are removed selectively by means of a blood detoxification procedure.

3. Method according to claim 1 or 2, characterized in that the particles are removed by precipitation, filtration, chromatography and/or adsorption.

4. Method according to claim 3, characterized in that the precipitation is carried out with a polyanion or a polycation as the precipitating agent.

5. Method according to claim 4, characterized in that the polyanion for precipitation is selected from the group consisting of heparin, dextran sulfate, and phosphotungstic acid.

6. Method according to claim 3, characterized in that the filtration is carried out by cascade filtration involving the use of at least two filter systems.

7. Method according to claim 3, characterized in that the adsorption is carried out by means of electrostatic interactions between the particles, which possess charged groups or are ionizable, and a correspondingly oppositely charged or ionizable adsorbent material.

8. Method according to claim 7, characterized in that the particles carry positively charged or chargeable groups, and polyacrylamide or dextran sulfate is used as the adsorbent material.

9. Method according to claim 3, characterized in that the adsorption is carried out by means of immunoadsorption.

10. Method according to anyone of the preceding claims, characterized in that the particles that are removed comprise liposomes.

11. Method according to anyone of the claims 1 through 9, characterized in that the particles that are removed comprise selectively removable cell types, lipoprotein particles, virus particles or polymer particles.

12. Method according to anyone of the preceding claims, characterized in that the withdrawn body fluid comprises whole blood or tissue fluid.

13. Method according to anyone of the preceding claims, wherein the particles to be removed served as drug carriers in a preceding medical therapy.

14. Method according to claim 13, wherein the therapeutic agents are selected from the group consisting of cytostatic agents, antibiotics, antivirals, antimycotic agents, substances used in gene therapy, antibodies, interferons, cytokines, and radionuclides.

15. Method according to claim 13 or 14, characterized in that the active agent-containing or -carrying particles are recovered after their removal from the body fluid.

16. Method according to anyone of the preceding claims, characterized in that the particle-mediated complete or partial elimination of a toxic and/or harmful substance is carried out in order to adjust the content of the corresponding substance or for dose adjustment or for adjustment of the time course of a therapeutic regimen of a therapeutic agent.

17. Method according to claim 16, characterized in that the adjustment involves that the content of the eliminated substance and/or the particle employed is determined.

18. Method according to anyone of the preceding claims, wherein endogenous toxic or harmful substances are being eliminated.

19. Method for medical therapy, characterized in that the administration of a therapeutic agent or composition containing the therapeutic agent is followed by performing a procedure for at least partial elimination of the therapeutic agent or composition, said procedure being in accordance with anyone of the claims 1 through 17.

28. Use according to anyone of the claim 25 through 27, characterized in that the liposomes are removed by means of any of the procedures specified in claims 1 through 9.

20. Kit for medical therapy or research, comprising:

a) a preparation of particles that are capable of binding, taking up and/or carrying therapeutic agents, and

b) means for removing the particles from body fluids.

21. Kit according to claim 20, characterized in that the particles are selected from the group consisting of liposomes, selectively removable cell types, lipoproteins, and polymer particles.

22. Kit according to claim 20 or 21, characterized in that the particles as such already encapsulate therapeutic agents.

23. Kit according to anyone of the claims 20 through 22, characterized in that the means for removing the particles from body fluids correspond to the means suited to perform any of the procedures specified in claims 3 through 9.

24. Kit according to anyone of the claims 20 through 23, characterized in that the therapeutic agents are selected from the group consisting of cytostatic agents, antibiotics, antivirals, antimycotic agents, substances used in gene therapy, antibodies, interferons, cytokines, and radionuclides.

25. Use of liposomes for eliminating toxic and/or harmful substances from the human body.

26. Use according to claim 25, characterized in that the toxic substance is a therapeutic agent and the agent-loaded liposomes are used for treatment of diseases.

27. Use according to claim 25 or 26, characterized in that agent-loaded liposomes are applied and, after a time interval, at least partially removed from the body.

29. Method for eliminating potentially toxic and/or harmful substances from a liquid, said method comprising the following steps:

contacting the liquid, in which particles had been provided that are capable of binding, taking up and/or carrying the toxic and/or harmful substances, with at least one means selected from the group consisting of precipitation means, filtration means, chromatographic means, and adsorption means, and

separating the liquid and the particles as the result of the contact to the means.

30. Method according to claim 29, wherein the liquid comprises a body fluid.

31. Method according to claim 29 or 30, wherein liposome particles had been provided in the liquid.